Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 7, 2010, Pages 988-992

  O'Dowd, Caroline ^a   McRae, Laura A ^a,b   McMillan, Donald C ^b   Kirk, Alan ^c   Milroy, Robert ^a  

^a STOBHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

Albumin; C reactive protein; Non small cell lung cancer; Surgery; Survival; Tumor stage; White cell count

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASMS, SQUAMOUS CELL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954428188     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181da78f9     Document Type: Article

References (33)

1. Cancerstats, 2004. Available at: www.cancerresearchuk.org. Accessed June 2006.
2. Sign Guideline 80. Available at: http://www.sign.ac.uk. Accessed June 2006.
3. Wagner KJ. Surgical management of non-small cell lung cancer. Semin Oncol Nurs 2008;24:41-48.
4. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
5. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717. (Pubitemid 27260107)
6. Milroy R. Staging of lung cancer. Chest 2008;133:593-595. (Pubitemid 351367364)
7. O'Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 2000;37:36-40. (Pubitemid 30650664)
8. McMillan DC, Elahi MM, Sattar N, et al. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001;41:64-69. (Pubitemid 34666222)
9. Maltoni M, Caraceni A, Brunelli C, et al. Steering Committee of the European Association for Palliative Care. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations\a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005;23:6240-6248. (Pubitemid 46300243)
10. Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-267.
11. Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003; 89:1028-1030. (Pubitemid 37239206)
12. Wilop S, Crysandt M, Bendel M, et al. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie 2008; 31:665-670.
13. Koch A, Fohlin H, Sörenson S. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 2009;4:326-332.
14. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90:215-219. (Pubitemid 36237897)
15. Jamieson NB, Glen P, McMillan DC, et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005;92:21-23. (Pubitemid 40188430)
16. Crumley AB, McMillan DC, McKernan M, et al. An elevated C-reactive protein concentration prior to surgery predicts poor cancer specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006;94:1568-1571. (Pubitemid 43924914)
17. Lamb GW, McMillan DC, Ramsey S, et al. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer 2006;94:781-784.
18. Hara M, Matsuzaki Y, Shimuzu T, et al. Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 2007;27: 3001-3004. (Pubitemid 47228036)
19. Jones JM, McGonigle NC, McAnespie M, et al. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 2006;53:97-101. (Pubitemid 43831357)
20. Lee JG, Cho BC, Bae MK, et al. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer 2009;63:106-110.
21. Muller T, Marshall RJ, Cooper EH, et al. The role of serum tumour markers to aid the selection of lung cancer patients for surgery and the assessment of prognosis. Eur J Cancer Clin Oncol 1985;21:1461-1466. (Pubitemid 16196236)
22. Kasprzyk M, Dyszkiewicz W, Zwaruń D, et al. [The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer.] Pneumonol Alergol Pol 2008;76:321-326.
23. Roxbburgh C, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-163.
24. Ikeda M, Natsugoe S, Ueno S, et al. Significant host-and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003;238:197-202. (Pubitemid 38174493)
25. Canna K, McMillan DC, McKee RF, et al. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer 2004;90:1707-1709. (Pubitemid 38725638)
26. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454. (Pubitemid 29084777)
27. Riesco A. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 1970;25:135-140.
28. Vigano A, Bruera E, Jhangri GS, et al. Clinical survival predictors in patients with advanced cancer. Arch Intern Med 2000;160:861-868. (Pubitemid 30165248)
29. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004;30:261-277. (Pubitemid 39546229)
30. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008;44:1124-1132.
31. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008;67:257-262.
32. Koch A, Fohlin H, Sorenson S. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 2009;4:326-332.
33. Jones M, McGonigle N, McAnespie M, et al. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 2006;53:97-101. (Pubitemid 43831357)